Uses of medication: Imfinzi (Durvalumab) is (PD-L1) blocking antibody used for the treatment of patients with:
- Metastatic Urothelial Carcinoma
- Non-Small Cell Lung Cancer
Dosage: The recommended durvalumab dose is 10 mg/kg, which should be administered as an intravenous infusion over 60 minutes every 2 weeks, until the disease progression or unacceptable toxicity.
Treatment Reactions: The commonly reported imfinzi side effects in patients with urothelial carcinoma include: fatigue, musculoskeletal pain, constipation, nausea, peripheral edema, decreased appetite and urinary tract infection.
The commonly reported imfinzi side effects in patients with non-Small Cell Lung Cancer include cough, fatigue, pneumonitis/radiation pneumonitis, dyspnea, upper respiratory tract infections, and rash.
Warnings and Precautions:
- Patients should be monitored for the signs/symptoms of hepatitis, during and following the discontinuation of imfinzi 500mg therapy.
- Patients should be monitored for thyroid function before and periodically during durvalumab 120 mg treatment.
- Patients should be monitored for the abnormal renal function tests before and periodically during durvalumab treatment.
- Patients receiving treatment with Imfinzi injection 500 mg should be monitored for hyperglycemia or other signs/symptoms of diabetes.
- Women with childbearing potential and receiving durvalumab lung cancer drug, should avoid becoming pregnant.